Improved health-related quality of life during peptide receptor radionuclide therapy in patients with neuroendocrine tumours

IF 3.3 4区医学 Q2 ENDOCRINOLOGY & METABOLISM

Journal of Neuroendocrinology Pub Date : 2023-09-25 DOI:10.1111/jne.13342

Katarina Edfeldt, Per Hellman, Dan Granberg, Pernilla Lagergren, Espen Thiis-Evensen, Anders Sundin, Camilla Andersson

{"title":"Improved health-related quality of life during peptide receptor radionuclide therapy in patients with neuroendocrine tumours","authors":"Katarina Edfeldt, Per Hellman, Dan Granberg, Pernilla Lagergren, Espen Thiis-Evensen, Anders Sundin, Camilla Andersson","doi":"10.1111/jne.13342","DOIUrl":null,"url":null,"abstract":"Neuroendocrine tumours (NETs) can arise in different locations in the body, and may give rise to hormonal symptoms, which amongst other factors may affect patients' health-related quality of life (HRQoL). Up to four cycles of peptide receptor radionuclide therapy (PRRT) have been shown effective for symptom alleviation and prolonging progression-free survival. The aim of this study was to assess the patient's perspective regarding changes in their HRQoL during PRRT. HRQoL was assessed using the questionnaires for cancer in general, EORTC QLQ-C30, and the gastrointestinal NET-specifically EORTC QLQ-GINET21. Patients with NET (n = 204) rated their HRQoL before PRRT cycles one and four. The medical records of patients were reviewed and their HRQoL was compared to a matched reference population (n = 4910). HRQoL was found to improve during PRRT in aspects of global quality of life; role, social, and emotional functioning, and multiple symptom relief. Potential risk groups for worse HRQoL during PRRT were patients with overweight (BMI >25) who completed four cycles of PRRT and older patients (>65 years old). In conclusion, we found that PRRT improves HRQoL in patients with NETs. The results of this study may be used to improve person-centred care.","PeriodicalId":16535,"journal":{"name":"Journal of Neuroendocrinology","volume":"35 10","pages":""},"PeriodicalIF":3.3000,"publicationDate":"2023-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/jne.13342","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Neuroendocrinology","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/jne.13342","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}

引用次数: 0

Abstract

Neuroendocrine tumours (NETs) can arise in different locations in the body, and may give rise to hormonal symptoms, which amongst other factors may affect patients' health-related quality of life (HRQoL). Up to four cycles of peptide receptor radionuclide therapy (PRRT) have been shown effective for symptom alleviation and prolonging progression-free survival. The aim of this study was to assess the patient's perspective regarding changes in their HRQoL during PRRT. HRQoL was assessed using the questionnaires for cancer in general, EORTC QLQ-C30, and the gastrointestinal NET-specifically EORTC QLQ-GINET21. Patients with NET (n = 204) rated their HRQoL before PRRT cycles one and four. The medical records of patients were reviewed and their HRQoL was compared to a matched reference population (n = 4910). HRQoL was found to improve during PRRT in aspects of global quality of life; role, social, and emotional functioning, and multiple symptom relief. Potential risk groups for worse HRQoL during PRRT were patients with overweight (BMI >25) who completed four cycles of PRRT and older patients (>65 years old). In conclusion, we found that PRRT improves HRQoL in patients with NETs. The results of this study may be used to improve person-centred care.

Abstract Image

查看原文本刊更多论文

神经内分泌肿瘤患者在肽受体放射性核素治疗期间改善了健康相关的生活质量。

神经内分泌肿瘤（NETs）可能出现在身体的不同位置，并可能引起激素症状，除其他因素外，激素症状可能影响患者的健康生活质量（HRQoL）。多达四个周期的肽受体放射性核素治疗（PRRT）已被证明对缓解症状和延长无进展生存期有效。本研究的目的是评估患者对PRRT期间HRQoL变化的看法。使用癌症总体问卷、EORTC QLQ-C30和胃肠道NET-特异性EORTC QLQ-GINET21评估HRQoL。NET患者（n = 204）在PRRT周期1和4之前对其HRQoL进行评级。回顾患者的医疗记录，并将其HRQoL与匹配的参考人群（n = 4910）。研究发现，在PRRT期间，HRQoL在全球生活质量方面有所改善；角色、社交和情感功能，以及多种症状的缓解。PRRT期间HRQoL恶化的潜在风险组是完成四个周期PRRT的超重（BMI＞25）患者和老年患者（＞65 岁）。总之，我们发现PRRT可以改善NETs患者的HRQoL。这项研究的结果可用于改善以人为中心的护理。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Neuroendocrinology 医学-内分泌学与代谢

CiteScore

6.40

自引率

6.20%

发文量

137

审稿时长

4-8 weeks

期刊介绍： Journal of Neuroendocrinology provides the principal international focus for the newest ideas in classical neuroendocrinology and its expanding interface with the regulation of behavioural, cognitive, developmental, degenerative and metabolic processes. Through the rapid publication of original manuscripts and provocative review articles, it provides essential reading for basic scientists and clinicians researching in this rapidly expanding field. In determining content, the primary considerations are excellence, relevance and novelty. While Journal of Neuroendocrinology reflects the broad scientific and clinical interests of the BSN membership, the editorial team, led by Professor Julian Mercer, ensures that the journal’s ethos, authorship, content and purpose are those expected of a leading international publication.